text:
5 Financial Stocks Nudging The Sector Higher
TheStreet highlights 5 stocks pushing the financial sector higher today.
TheStreet Wire and Chris Dow
Dec 18, 2013 12:02 PM EST
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 22 points (0.1%) at 15,897 as of Wednesday, Dec. 18, 2013, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,497 issues advancing vs. 1,411 declining with 169 unchanged.
The Financial sector currently sits up 0.2% versus the S&P 500, which is unchanged. Top gainers within the sector include HDFC Bank ( HDB), up 4.5%, Woori Finance Holdings ( WF), up 3.7%, Mitsubishi UFJ Financial Group ( MTU), up 2.5%, Shinhan Financial Group ( SHG), up 2.4% and Weyerhaeuser ( WY), up 1.8%. On the negative front, top decliners within the sector include E-House China Holdings ( EJ), down 4.8%, Icahn ( IEP), down 3.0%, KKR ( KKR), down 2.1%, American Capital Agency ( AGNC), down 1.8% and Annaly Capital Management ( NLY), down 1.0%.
TheStreet would like to highlight 5 stocks pushing the sector higher today:
5. Toronto-Dominion Bank ( TD) is one of the companies pushing the Financial sector higher today. As of noon trading, Toronto-Dominion Bank is up $0.57 (0.6%) to $90.88 on average volume. Thus far, 149,917 shares of Toronto-Dominion Bank exchanged hands as compared to its average daily volume of 352,500 shares. The stock has ranged in price between $90.28-$91.06 after having opened the day at $90.30 as compared to the previous trading day's close of $90.31.
The Toronto-Dominion Bank, together with its subsidiaries, provides financial and banking services in North America and internationally. Toronto-Dominion Bank has a market cap of $83.0 billion and is part of the banking industry. The company has a P/E ratio of 13.6, below the S&P 500 P/E ratio of 17.7. Shares are up 7.1% year to date as of the close of trading on Tuesday. Currently there are 3 analysts that rate Toronto-Dominion Bank a buy, no analysts rate it a sell, and 1 rates it a hold.
TheStreet Ratings rates Toronto-Dominion Bank as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, expanding profit margins, increase in stock price during the past year and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Toronto-Dominion Bank Ratings Report now.
3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
4. As of noon trading, Manulife Financial Corporation ( MFC) is up $0.10 (0.5%) to $18.72 on light volume. Thus far, 426,004 shares of Manulife Financial Corporation exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $18.60-$18.79 after having opened the day at $18.63 as compared to the previous trading day's close of $18.62.
Manulife Financial Corporation, together with its subsidiaries, provides financial protection and wealth management products and services to individual, corporate, and business customers primarily in Asia, Canada, and the United States. Manulife Financial Corporation has a market cap of $34.4 billion and is part of the insurance industry. The company has a P/E ratio of 13.1, below the S&P 500 P/E ratio of 17.7. Shares are up 37.0% year to date as of the close of trading on Tuesday. Currently there are 6 analysts that rate Manulife Financial Corporation a buy, no analysts rate it a sell, and 1 rates it a hold.
TheStreet Ratings rates Manulife Financial Corporation as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Manulife Financial Corporation Ratings Report now.
3. As of noon trading, UBS ( UBS) is up $0.10 (0.6%) to $18.36 on light volume. Thus far, 674,817 shares of UBS exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $18.34-$18.43 after having opened the day at $18.39 as compared to the previous trading day's close of $18.26.
UBS AG, a financial services firm, provides wealth management, asset management, and investment banking products and services worldwide. Its Wealth Management division provides financial services to high net worth individuals worldwide. UBS has a market cap of $70.6 billion and is part of the banking industry. The company has a P/E ratio of 17.0, below the S&P 500 P/E ratio of 17.7. Shares are up 16.8% year to date as of the close of trading on Tuesday. Currently there is 1 analyst that rates UBS a buy, no analysts rate it a sell, and 1 rates it a hold.
TheStreet Ratings rates UBS as a sell. Among the areas we feel are negative, one of the most important has been poor profit margins. Get the full UBS Ratings Report now.
2. As of noon trading, Fidelity National Financial ( FNF) is up $0.42 (1.4%) to $30.81 on average volume. Thus far, 1.8 million shares of Fidelity National Financial exchanged hands as compared to its average daily volume of 3.3 million shares. The stock has ranged in price between $30.44-$30.99 after having opened the day at $30.46 as compared to the previous trading day's close of $30.39.
Fidelity National Financial, Inc. provides title insurance, mortgage services, and diversified services in the United States. Fidelity National Financial has a market cap of $7.4 billion and is part of the insurance industry. The company has a P/E ratio of 14.1, below the S&P 500 P/E ratio of 17.7. Shares are up 27.7% year to date as of the close of trading on Tuesday. Currently there are 2 analysts that rate Fidelity National Financial a buy, no analysts rate it a sell, and 1 rates it a hold.
TheStreet Ratings rates Fidelity National Financial as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Fidelity National Financial Ratings Report now.
1. As of noon trading, Aon plc ( AON) is up $0.57 (0.7%) to $82.39 on light volume. Thus far, 477,486 shares of Aon plc exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $81.74-$82.46 after having opened the day at $82.00 as compared to the previous trading day's close of $81.82.
Aon plc provides risk management services, insurance and reinsurance brokerage, and human resource consulting and outsourcing services worldwide. Aon plc has a market cap of $24.6 billion and is part of the insurance industry. The company has a P/E ratio of 24.6, above the S&P 500 P/E ratio of 17.7. Shares are up 47.1% year to date as of the close of trading on Tuesday. Currently there are 3 analysts that rate Aon plc a buy, no analysts rate it a sell, and 11 rate it a hold.
TheStreet Ratings rates Aon plc as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, impressive record of earnings per share growth, solid stock price performance and increase in net income. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Aon plc Ratings Report now.
If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the financial sector could consider Financial Select Sector SPDR ( XLF) while those bearish on the financial sector could consider Proshares Short Financials ( SEF).
MarketsStocksMidday Bell
How Can a Stock Gain on Missed Earnings Expectations? Jim Cramer Explains
Stocks don't live and die on earnings reports. Jim Cramer breaks down how stocks can have unexpected reactions to earnings reports.
Daniel Kuhn


The Fifth Season's curator Esther Vossen has given them a tour of the terrain of the mental health institute and helped them feel at home during the next three months in the residency. The artists are researching how psychiatry can influence their work. To be able to do this, they are working together with the staff and patients of the institute. They will present their work at the end of March.
Teacher of the group is George Korsmit, who did a residency in The Fifth Season with his partner Saskia Janssen in 2013.
Since 2014, The Fifth Season has made it a tradition to invite different art academies each year to say in the residency. This way, beginning artists get the opportunity to research what role art can play in a social context and how specific surroundings can stimulate and enrich this research and the making of new works of art.
Art academies that The Fifth Season has previously invited are: Sandberg Institute (Cure Master with Martijn Engelbregt), ArtEZ with Lado Darakhvelidze, Gerrit Rietveld Academie with Vincent Zedelius and Hanne Hagenaars and the HKU with Frank Koolen and Anno Dijkstra.


text:
by Daniel Komesch
Mary Simon completed her first significant task as the newly installed Governor General yesterday, dissolving the 43rd parliament and issuing the writs for what has been a long-anticipated federal election.
The 44th federal election was not scheduled to take place until October 16, 2023, but Justin Trudeau and the Liberals will try to take advantage of solid polling numbers and the 'halo effect' that effective vaccine procurement and distribution has delivered to the party, in the hopes of securing a majority government.
At Rideau Hall on Sunday morning, Prime Minister Trudeau highlighted that the last 17 months have been like nothing we have ever experienced before, consequential decisions have been made, and Canadians should have the opportunity to weigh in on not just how the pandemic has been managed to date, but what the future looks like moving forward. In short, his justification for the election call yesterday, is that we are at a pivotal moment in history, and Canadians should have their say in how we end the pandemic and "build back better."
Out of the gate, it's clear that the tools which government might use to stamp out the remainder of the pandemic will feature heavily in the campaign, including conversations about mandatory vaccines and vaccine passports.
Why now? Timing is everything
The government's ability to effectively procure vaccines was always going to feature prominently in their electoral chances, either now or down the line. Today, over 62 million vaccines have been delivered, 72 per cent of all eligible Canadians are fully vaccinated, 82 per cent of those eligible have at least one dose, and a plan to construct a domestic mRNA vaccine production facility was just announced. On vaccine procurement, the Liberals consider it mission accomplished (or at least, mission accomplished to date) and hope that in exchange for the jabs in shoulders they have delivered to Canadians, Canadians will in turn deliver an "X" beside the names of Liberal candidates on the ballot.
Further, with the talk of a fourth wave of the pandemic casting a long shadow over Canadians, the Liberals know they have a small window of opportunity in which a federal election could credibly be conducted. While we've seen pandemic elections across several provinces – and the incumbents rewarded– a federal campaign is always a bigger beast, and an outbreak in any region of the country will be of serious concern but will reinforce the opposition's criticism that the Liberals' motivation represents an opportunistic bid to secure a majority. If the looming fourth wave is like the last, case counts likely won't begin to rise significantly until mid-fall, providing the Liberals the smallest of windows to act.
But why do we need an election, anyways? Events, dear boy, events
Canada, like all countries the globe over, has taken its lumps over the course of the pandemic. We've lost lives and livelihoods, and all Canadians have felt the pressures of lockdowns. The pandemic has left its mark on every inch of society and the economy, and while the current government's response will no doubt be a topic of high relevance during the campaign, as vaccine distribution creates light at the end of the tunnel, this election may be more about how Canada will rebuild on the other side, and how each of the parties intends to do it.
For example, parties will have to detail to Canadians how they'll deal with the fiscal toll the pandemic has imposed, including inflation; how they will build resiliency in our health care systems to ensure that from primary to emergency to long-term care, Canadians are protected; how we'll build domestic capacity to manufacture critical goods; how we plan to bring the economy back to full steam, and; how Canada will respond to other threats that are lurking in the background, or as is climate change, already bearing down on us at full speed. The world changed forever with COVID-19 and this federal election will be a referendum on who Canadians can trust to take them through to the other side.
The Campaign Watch List
While it may yet be early to divine what the "ballot box question" will be, some of the issues we expect to see topping headlines and platforms alike are:
Health + Wellness: Health is currently front-of-mind for all Canadians, and how could it not be over 17 long months into a pandemic which has highlighted significant gaps in long-term care, mental health, and addictions treatment. While the Liberal government hasn't moved on universal pharmacare, the issue of drug prices is certainly alive. Expect health to feature prominently.
Jobs: Much of the current $355 billion federal deficit is being driven by delivery of financial supports to individuals and businesses. Getting back some much need fiscal breathing room will necessitate bringing our job market back to life. Each of the parties has pledges to create one million jobs and no doubt we are soon to get some more meat on the bone outlining how they expect to do it.
Truth and Reconciliation: While reconciliation has been a high priority for Liberal government for some time, with the recent discovery of mass graves at residential schools, the issue is making waves across the whole of the public sphere. Issues around truth and reconciliation and the equity of Indigenous Peoples in Canada will certainly sit near the top of the agenda for all parties.
Innovation + Science: Vaccine development has put the benefits of investing in science front-and-centre for many. The Liberals recently announced a biomanufacturing and life sciences strategy and the Conservatives have released initial plans to invest in the creation of a Canada Advanced Research Agency. Expect all parties to frame innovation as a means of achieving much needed economic growth.
Domestic Supply Chain Resilience: The pandemic highlighted serious gaps in Canada's ability to manufacture essential goods and exposed diplomatic fault lines where supply chain access was denied. Many countries, including Canada, are quickly realizing that in order to achieve dual goals of security and economic growth, enhanced levels of domestic manufacturing capacity will be necessary. Expect to hear words like on-shoring, re-shoring and ally-shoring a lot and expect all parties to put forth plans on what Canada can and should manufacture more of at home.
The Canada + U.S. Relationship: With the exit of Trump the Canada-U.S. relationship was expected to defrost, but there are still several issues keeping it thorny: Buy America, Line 5, and travel across the U.S. border. Any credible government will have a serious plan for dealing with our largest trading partner and closest ally, so expect the Canada-U.S. relationship to be a topic that comes up often.
Sustainability: The United Nations Secretary General sounded a global alarm this past week with the release of the most recent Intergovernmental Panel on Climate Change report that suggested the impacts of climate change are accelerating faster than anyone had predicted and without swift and coordinated action, the planet is at serious risk. Climate change credibility will be a necessity for any party to win in this election.
Party Priorities
Heading into the campaign, here's how we see each of the party's priorities shaping up:
The Liberal Party
Job #1: Win a majority government
Priorities: Managing the pandemic; Jobs and economic growth; Affordability for the middle class; Climate change and clean energy; Childcare; Indigenous reconciliation; Status of women.
Watch for: Both Justin Trudeau and NDP Leader Jagmeet Singh like to spar – with a weakened Conservative Party and Singh's popularity trending towards heavyweight, expect Trudeau will save at least a few haymakers for a surging Singh in the hopes that he can keep the NDP vote down for the count.
The Conservative Party
Job #1: Win government
Priorities: Jobs and economic recovery; Mental health; Accountability and ethics; Pandemic preparedness; Balanced budget over 10 years; Targeting rank and file union workers.
Watch for: The Conservatives have positioned themselves early with the release of their Unleashing Innovation Plan – watch for them to take the reins on conversations about innovation as a key driver of economic growth and jobs. With a growing number of parties on the right side of the spectrum, also expect that leader Erin O'Toole will be watching his flanks to ensure the likes of the Maverick Party (formerly known as Wexit Canada) and People's Party of Canada (PPC) aren't siphoning off too many votes.
The NDP
Job #1: Keep up the momentum and grow their share of seats
Priorities: Universal pharmacare and dental care; Curbing inequality; Supporting workers; Environment and climate change; Diversity, equity and inclusion; Affordable housing.
Watch for: The NDP will put serious emphasis on pulling out the youth vote, where the NDP are particularly popular. Also watch for the NDP to highlight the role they played through the pandemic and frame it as forcing the government's hand to increase and enhance the supports that were made available.
The Bloc Québécois
Job #1: Be seen as the champion for Quebecers in Ottawa
Priorities: Amplify Assemblée Nationale concerns in Ottawa; Benefit from François Legault's popularity by supporting his issues; Climate change and the environment; culture.
Watch for: The Bloc picked up a record number of seats in the last election – they currently hold 32 and see the Liberals as their biggest threat in the province. Leader Yves-Francois Blanchet will attempt to paint the Liberals as out of touch with the opinions of Quebecers on language, secularism and the environment as he tries to pick up seats, with a focus on Montréal.
The Green Party
Job #1: Stop the bleeding and retain at least one seat
Priorities: Environment and climate change; Transition to a green economy; social inclusion.
Watch for: The Green Party has been their own worst enemy for months with infighting causing one MP to cross the floor and leader Annamie Paul's future ever uncertain. To have any chance of retaining at least one of the two seats they currently occupy, the Green Party is going to have to come out with a new united front.
Daniel Komesch
Read articles by Daniel Komesch
Learn more about our Public Affairs specialist expertise

redpajama_set_name: RedPajamaCommonCrawl


ВНИМАНИЕ! Только сегодня в интернет-магазине WDrake WW распродажа товаров в категории "": СКИДКА на Toaster Oven Crisping Pan by Home-Style Kitchen составляет 62% !!!
The holes in this unique non-stick toaster oven pan ensure crusts cook up crisp and delicious. Toaster oven tray is perfect for pizza, frozen french fries, garlic bread, and more. 11 1/4" L x 6 7/8" W. Aluminum. Hand wash. Made in USA.


A brand new collaboration this coming year: ARTVARK Saxophone Quartet with the collective Drums United led by latin drummer Lucas van Merwijk.
PROGRAMMERS ATTENTION, because this project will play at the festivals around the summer of 2019 and will go into the theaters at the beginning of 2020. Both groups together on stage for the first time.
In addition to Lucas van Merwijk, Drums United consists of Marco Toro (Venezuela), Alper Kerkeç (Turkey) and Moussé Pathé (Senegal).
ASQ & DU will take you on a timeless trip, past a meditative coral with melodious percussion to a steaming saxophone solo over a deep, exciting groove.
We know DRUMS UNITED from their shows 'Heartbeat' and 'Rhythm Dreams', spectacular drums and percussion by top percussionists from four continents: Africa, South America, Asia and Europe.
Drums United toured all over the world and since 2001 has been led by Lucas van Merwijk: in 2015 by the readers of the Slagwerkkrant again voted the best World & Fusion drummer of the Benelux.


Twitter has no immediate plans to raise money or to go public, and a report that the company was in talks to sell JPMorgan a 10 percent stake was "made up," co-founder Biz Stone said Thursday.
In an exclusive interview with Reuters Twitter was not focussed on positioning itself to make an initial public offering. "We have so many other things before we even think about that," he said. "We are not even discussing it internally. It's too far off."
As one of the hottest companies in Silicon Valley Twitter must suffer constant curiosity about its IPO thinking, especially as the market warms to internet start-ups again. The popular professional networking site LinkedIn has announced it will go public, and Facebook, valued at some $50 billion on non-public paper, said it would do so or at least provide public-company-level financials starting next year.
Stone flatly told Reuters: "(The report is) made up."


text:
O futebol é o esporte mais popular em Cabo Verde . A liga é dividida em onze divisões, sendo uma para cada ilha, tirando duas ilhas, Santiago e Santo Antão, que possuem duas zonas desde 2000. A federação de futebol é uma federação que é conhecida como a Federação Cabo-verdiana de Futebol, tornou-se afiliada à CAF em 1986 e mais tarde à FIFA em 2001. Ela também é filiada à WAFU.

Divisões
O país possui onze divisões em nove ilhas, sete têm uma liga insular e duas contém duas zonas cada, juntamente com as competições de taça, supertaça e torneio de abertura.

Campeonatos Regionais
A cor azul indica que a liga tem primeira e segunda divisões.

Taças regionais

Super Taças regionais

Taça da Associação
Embora equivalente à Taça da Liga usada em outros países, Cabo Verde é uma das poucas nações a ser rotulada como um desafio do "torneio de abertura". Alguns se tornaram conhecidos como uma Taça da Associação em Boa Vista e São Vicente. A cor azul indica uma competição com primeira e segunda divisões, clubes em diferentes divisões competem no torneio da mesma divisão.

História
O futebol foi introduzido pela primeira vez no país por volta de 1910, a primeira área em que foi introduzida foi a ilha de São Vicente, mais tarde foi introduzida na ilha de Santiago, depois no Sal. O CS Mindelense, sediado na ilha de São Vicente, é o clube mais antigo de Cabo Verde fundado em 1919 e tornou-se membro oficial em 25 de maio de 1922. O segundo mais antigo é o primeiro clube de futebol da ilha de Santiago chamado Sporting Clube da Praia., mais tarde fundado o FC Derby, fundado em 5 de agosto de 1929, dois anos depois, na mesma cidade, foi fundado o Vitória FC, dois dos clubes foram os primeiros nomeados após um clube português. A competição oficial só começou em 1938 e o Mindelense foi o primeiro clube a conquistar um título regional. O título colonial era então oficial. Também ao mesmo tempo, a terceira ilha a ter um clube de futebol era Sal onde o SC Santa Maria foi fundado na então ilha capital, mais tarde em 1952, a quarta ilha a ter um clube seria Boa Vista com Sport Sal Rei Club .

Campeonatos nacionais
A primeira competição de futebol de ilha inteira começou no início dos anos 50 e o CS Mindelense ganhou seu primeiro título em 1953, então, estas competições eram territoriais desde que era uma província ultramarina de Portugal até sua independência em julho de 1975. Antes, existia apenas a competição de São Vicente que começou em 1937 e durou até 1953. Os clube das ilhas de São Vicente e Santiago eram seus únicos participantes. Várias competições foram canceladas, incluindo em 1954 e entre 1956 e 1957. Outros cancelamentos ocorreram quando o último jogo antes da independência jogou e ganhou seu último título. Ao contrário de outras províncias portuguesas da época, o Mindelense foi o único clube a competir na copa de Portugal e participou duas vezes em 1966  em 1971, a menor de todas as províncias do país (mais tarde províncias autónomas) do Império Português. . O primeiro jogo após a independência foi em 1975 e seu primeiro título foi reivindicado pelo CS Mindelense em 1976. Os dois últimos cancelamentos ocorreram em 1979, 1982 e 1986. A partir de 1976, um clube de qualquer das ilhas poderia participar.

No início dos anos 80, a criação de mais times de futebol levou à criação de uma nova divisão na década de 1990 que se tornou baseada em ilhas, exceto por uma delas na época apenas seis e depois sete, sendo uma delas qualificada para as duas. grupos. Em meados da década de 1990, a divisão foi dividida em nove, que se classificaram em três grupos, A, B e C, e agora foram adicionadas 11 novas zonas insulares para Santiago e Santo Antão e o Grupo C foi reduzido a seu sistema de dois grupos. Por várias vezes, o campeão seria decidido pelo maior número de pontos e gols em 2001 e 2002, o maior número de pontos já foi 19, nove clubes participaram dos campeonatos nacionais até 2003. O Sporting Praia detém o maior número de golos marcados na temporada regular e o número total de 35 em 2005. Ainda na temporada, o Sporting Praia marcou 13-0 no Desportivo Estância Baixo, sendo a maior goleada nos campeonatos nacionais até hoje. Zé di Tchétcha marcou os maiores golos nos campeonatos, totalizando 14. O campeão do ano completaria a competição nacional do ano seguinte, que começou em 2005 e elevou o total de clubes de campeonatos nacionais para doze, um número está hoje. A temporada 2009 seria a primeira competição final que contou com dois clubes de uma única ilha (Santiago) ou cidade (Praia), voltaria a realizar em 2010 e recentemente em 2015 (Derby e Mindelense do Mindelo na ilha de São Vicente), A maioria dos jogos finais com dois dos clubes foi com Sporting Praia e Mindelense quatro vezes (em 1977, 1988, o Mindelense e Botafogo (em 1976, 1980 e 1981) por três vezes e Mindelense e Académica do Porto Novo (em 2012 e 2016). O Sporting Praia e o CS Mindelense conquistaram, cada um, quatro títulos consecutivos, o primeiro Sporting Praia entre 2006 e 2009 e o Mindelense desde 2013. Na temporada de 2017 que começa em meados de maio, o sistema triangular será devolvido e contará com quatro clubes em cada um dos três grupos, o restante de cada campeão da associação regional (alguns deles com sua própria Premier / Primeira Divisão) e terá a fase final, o campeão da época anterior qualificado e a Mindelense será colocada no Grupo A.

O CS Mindelense detém o maior número de títulos nacionais conquistados, totalizando doze.

Competições regionais / ilha
Por volta de 1995, a zona sul de Santiago se tornou a primeira zona a apresentar uma primeira e segunda divisões, seguida por Fogo e São Vicente em 2008, o norte de Santo Antão em 2013, Sal em 2014 e Maio, o mais recente em 2015. A Liga do Norte de Santiago é a única liga a ter as primeiras e últimas fases, os grupos norte e centro-norte existiam nos primeiros anos e em 2010 o sistema de grupos foi eliminado e até 2015 todos os 13 clubes competiram na primeira fase e os quatro primeiros se elevam para a segunda fase e o vencedor foi decidido pelo maior número de pontos e gols. Garridos é o único clube a mudar as divisões regionais do norte ao sul de Santiago em 2011, pois sua localização é no sul da ilha. No início de 2010, em vez de dois clubes diretamente relegando, os jogos promocionais / não-aumentados foram introduzidos e um sistema de dois jogos é apresentado nos campeonatos regionais de Fogo, Santiago Norte e Sul (não em 2016) Zonas e São Vicente, o clube com o maior número de pontos fica ou é promovido, o clube com menos ou será promovido ou não será promovido na temporada seguinte.

O maior número de clubes de qualquer ilha / liga regional é o sul de Santiago, o menor é o de Brava, o Maio o tinha esse título até 2015.

No início de 2010, Cabo Verde contaria com cerca de cem clubes de futebol em 11 competições regionais, algumas delas com duas divisões. Em 2014, seis novos clubes de futebol foram adicionados à Liga das Ilhas do Sal e a segunda divisão foi formada. Um ano depois, em 2015, quase todos os clubes (um deles foi suspenso) voltaram para a competição na Zona Norte de Santiago. alguns novos clubes foram adicionados e o sistema de duas divisões foi estabelecido, a liga regional contou com 26 jogos e registrou alguns gols, vitórias e pontos conquistados por alguns clubes, a temporada 2015-16 de Santiago do Norte foi a mais longa temporada regional de em qualquer uma das ligas regionais do país, Varandinha foi o vencedor de 2015/16 com um número recorde de pontos 63, sucedendo o total de 49 da Zona Sul do Sporting Praia que foi em 2005, a Zona Sul de Santiago foi a segunda mais longa e a terceira mais longo sendo Fogo. Até 2015, o Maio teve a menor temporada regional de qualquer uma das ligas regionais do país, a Brava tem a menor desde aquela época. A duração da temporada da Zona Norte de Santiago é agora a mesma da Zona Sul de Santiago. Alguns dos jogos da segunda divisão acontecem em maio e até junho, especialmente em Santiago do Norte.

Em 7 de fevereiro de 2017, por causa da falta de pagamento a alguns árbitros nas rodadas 17 e 26 da temporada anterior e as rodadas desta temporada, a temporada da Zona Norte de Santiago foi adiada por duas semanas, a competição regional foi retomada em 25 de fevereiro como os árbitros foram pagos quatro dias antes pelo patrocínio de duas empresas de telecomunicações, uma delas era a Cabo Verde Telecom e os municípios onde os clubes estão sediados.

Outros recordes incluem a melhor temporada que a Académica Porto Novo alcançou em 2012, que foram todas as vitórias. A maior sequência de invencibilidade de qualquer uma das ligas da ilha foi a Académica Porto Novo, que durou cerca de 50 a 60 jogos sem derrotas que duraram entre 2012 e 23 de abril de 2016, o recorde também terminou em jogos fora de casa que o CS perdeu. 1, o recorde continua nos jogos em casa. A Académica também tem um recorde combinado com os jogos da Taça e da Supertaça, mas não com a Taça de Santo Antão, que foi a primeira derrota na Taça que a Académica Porto Novo teve. A segunda é a Mindelense que durou de 29 de março de 2014 a 16 de abril de 2016 com a perda para Amarante, juntamente com a casa (iniciada a partir de 12 de janeiro) e fora de casa (até 24 de abril de 2016 com a derrota para Derby ).

Várias temporadas tiveram um clube ou dois jogadores inelegíveis por uma parte ou por toda a temporada, como FC Ultramarina e SC Atlético na temporada 2005 de São Nicolau e recentemente a Académica do Mindelo por cinco jogos com um falso guarda-redes para a época 2016-17 . Por algumas temporadas, houve disputas de campeonatos em uma das regiões, São Nicolau em 2005 e uma temporada, e a Primeira Divisão Santiago Norte incluindo Scorpion Vermelho e Varandinha em 2016 e AJAC da Calheta e Benfica Santa Cruz em 2017.

Taça, Supercopa, Torneio de Abertura e Troféu dos Campeões
As taças de Associação, assim como a copa insular e supercopa foram adicionados em 1985 na ilha de Santiago, mais tarde em 1999 na maioria das nove ilhas, a Boa Vista criou a sua em 2009, a Brava e o Maio foram as últimas em que a competição de copas e super copas foi criada em 2011 As competições da Supercopa incluem um campeão regional e um vencedor da copa regional. Em algumas temporadas, quando um clube ganha um campeonato e um título da copa, o segundo lugar da copa participa. A Zona Norte de Santiago não tem essas competições, nem mesmo o torneio de abertura O Torneio de Abertura (equivalente a uma Copa da Liga) possui apenas uma parte onde um clube concorre uma vez com um clube diferente das duas divisões, em São Vicente (incluindo as ilhas adjacentes) ), é conhecida como Associação Taça e possui duas divisões com uma porção onde um clube concorre uma vez com um clube diferente, estas ocorrem no início da temporada um mês (ou dois) antes do campeonato regional começar. O da Ilha da Boa Vista foi criado antes das competições da taça e super taça terem sido criadas em 2007. O Troféu do Campeonato foi implementado pela primeira vez em 2016, que apresenta o campeão da Premier e Segunda Divisões regionais em vários campeonatos regionais. A primeira foi a Taça dos Campeões de São Vicente, realizada no dia 15 de Outubro, que contou com Mindelense e Ribeira Bote, tendo o Mindelense ganho o seu primeiro e único título. Maio e Fogo também realizaram suas primeiras edições em novembro, onde venceram o Real Marítimo (Segunda Divisão) e Vulcânicos (Primeira Divisão). Existem três em Cabo Verde.

As competições nacionais de taças incluem a principal Taça de Cabo Verde, que teve início em 1982. O segunda temporada foi jogarado em 2007 e foi disputada durante quatro temporadas, tendo sido canceladas as competições de 2008  e 2011  e entre 2013 e 2017, e da Taça da Independência cabo-verdiana . Recentamente, o dois temporadas (2018 e 2019) de taça nacional foi jogarado em menses de maio e junho sem fase rodadas. A Supertaça Cabo-verdiana foi disputada em 2013 entre um campeonato e um vencedor da Taça, o Sporting Praia enfrentou a Onze Unidos e o Sporting Praia reivindicou o seu único título, a edição de 2014 foi desafiada pela segunda maior equipa do Sporting Praia. O Boavista Praia detém o maior número de títulos da Taça Nacional, numero dois.

Competições da CAF
O vencedor do campeonato nacional participa da Liga dos Campeões da CAF na temporada seguinte, o segundo colocado participa da Copa Confederativa CAF, o primeiro foi em 1992 e o recente foi o Sporting Clube da Praia em 2009. Durante alguns anos, um campeão e um segundo clube não apareceram na competição africana, especialmente entre 2002 e 2005, entre 2010 e 2015. Uma vez que o Sporting Praia, um não campeão, participou na edição de 2000. O segundo lugar participou da Copa CAF e da Taça dos Vencedores da CAF, desde sua fusão em 2004 até 2015, e não participou da Copa da Confederação da CAF. O CS Mindelense não tem como se qualificar para a Liga dos Campeões da CAF 2017. Como a Copa de Cabo Verde foi criada em 1982, o segunda edição jogarado em 2007, nenhum vencedor da Copa participou da Copa das Confederações, já que a Copa de Cabo Verde foi cancelada entre 2013 e 2017, não é certo que um clube se qualifique recentamente na Copa da Confederações de 2018 da CAF . Um total de seis clubes participaram incluindo Sporting Praia, Mindelense, FC Derby, Académica do Sal, Boavista Praia e Travadores, apenas um clube do SC Atlético foi desqualificado devido a que a federação de futebol não nomeou o participante a tempo.

Estádios em Cabo Verde

O estádio mais utilizado no país é o Estádio da Várzea, localizado na cidade da Praia, com capacidade para 8.000 pessoas. O maior estádio de Cabo Verde é o Estádio Municipal Adérito Sena, localizado em Mindelo, na ilha de São Vicente, com 12.000 lugares. A maioria dos locais de futebol na ilha é Santiago.

Notas

Ver também
 Campeonato Cabo-Verdiano
 Taça Cabo-Verdiano
 Super Taça Cabo-Verdiano

Futebol de Cabo Verde

redpajama_set_name: RedPajamaWikipedia


text:
'Support Memories Pizza' Fund Raises $35,000 in Just Four Hours
By bonnie,
April 2, 2015 in Religious Liberty Issues
bonnie 776
Past the 10,000 Mark
'Support Memories Pizza' Fund Raises $35,000 in Just Four Hours Cortney O'Brien | Apr 02, 2015
It's come to the point where we now have to create funding sites to defend our religious freedom. Nevertheless, that is just what radio host Dana Loesch did Wednesday night after Memories Pizza, a small pizza joint in Walkerton, Indiana, announced their support of the Religious Freedom and Restoration Act that has caused so much unnecessary contention. Crystal O'Connor, co-owner of Memories Pizza, spoke to Loesch about the sudden barrage of hate her and her dad had endured over the last 24 hours simply because they had stood by their principles.
"We are a Christian establishment," O'Connor told WBND-TV. "We're not discriminating against anyone, that's just our belief and anyone has the right to believe in anything."
Those comments stirred some vicious backlash from the 'tolerant' left. One of the most egregious responses had to be a threatening tweet from a softball coach at Walkerton's Concord Community High School. Before her account was deleted, she wrote, "Who's going to Walkerton, IN to burn down #memoriespizza w me?" Her message prompted other Twitter users to alert the local police department and the coach was swiftly suspended.
Lost in the attacks on the O'Connors, is the fact that the co-owner did not say Memories Pizza would refuse service to gays; she said they would not cater gayweddings. On Thursday morning's "Fox and Friends" on Fox News, Elisabeth Hasselbeck argued this was a clear distinction, considering a wedding caterer becomes almost a participant in the wedding, offering tastings before or after the ceremony and so forth. Yet, because of the severity of the threats the O'Connors were receiving, they were forced to close up shop.
The income Crystal was receiving from pizza sales was paying for her apartment, she told Loesch. Now, she said, she has no income coming in at all. That's when the outraged radio host announced she was starting a 'Support Memories Pizza' page on GoFundMe.com in order to help the business owners get back on their feet. People responded immediately:
Just one hour later, their goal would be achieved - and then some. The total currently stands at over $70,000.
This outpouring of support doesn't only come from Americans' love for pizza, but for religious liberty. The O'Connors don't deserve to be demonized for their beliefs, they deserve the same rights as any other American who dares to hold opinions that stray from the status quo. Hopefully this money gets them off the hit list and back in the kitchen!
Update: 'Support Memories Pizza' has now surpassed $100,000 in funding support. Keep watching the money pour in for religious liberty.
LifeHiscost and RudyEnext
Aliensanctuary 407
Aliensanctuary
Broke the 1000 mark
According to an MSNBC article, more than $828,000 has been raised in support of the Pizza store. Sounds like a really good way to make some extra cash.


In Pocket, Picture in Picture mode allows you to continue watching previously saved videos while using other apps on your iPad. Similarly, BBC iPlayer now lets you continue watching channels while using other apps.
And in Hulu's iOS app, Picture in Picture allows you to enjoy a video while doing something else, like reading email, browsing the web and more.
Introducing PiP: New Picture in Picture mode for live games (MLB.TV and MLB.TV Game of the Day) and video highlights (Supported iPad models only).
Spotlight Search: Use Spotlight to search for saved Titles and URLs and open them directly in Pocket's Article View.
Picture in Picture: Continue watching videos in Pocket while using other apps on your iPad.
Plenty of bug fixes and improvements made specifically for iOS 9.
Picture in Picture for iOS9 has arrived! After starting your video, get back to that email you have been meaning to write while binging on The Mindy Project.
This version adds support for the latest iOS update.
iPad (Mini 2, Mini 3, Air, Air 2) users with iOS 9 can continue to watch programmes while using other apps, press the home button during playback to give it a try.
Following your feedback we've corrected the order of favorites to show the latest programmes first.
To invoke Picture in Picture in supported apps, users simply press the Home button during video playback. The video then scales down to a corner of your Home screen and continues playing even while you use the other app.
The rectangular video overlay can be resized with the pinch-zoom gesture, dragged with your finger to change which corner it's docked to and flicked off the side of the screen. To bring it back into view, just tap on a small arrow at the screen edge.
And in a typical Apple fashion, Picture in Picture window automatically moves out the way when you bring up the software keyboard.
Picture in Picture is compatible with the iPad mini 2, iPad mini 3, iPad mini 4, iPad Air, iPad Air 2 and the upcoming iPad Pro. This mode is not available on iPhones.
By the way, the App Store is currently highlighting the best apps and games that are already equipped with iOS 9-specific features.
How do you like Picture in Picture so far?
Hulu, Pocket, MLB.com at Bat and BBC iPlayer are available free in the App Store.


You can watch The Invention of Lying on Jomovies.com... Set in a world where the concept of lying doesn't exist, a loser changes his lot when he invents lying and uses it to get ahead.. The so awaited release of The Invention of Lying was on 2009-09-13 and it has a total duration of 100 minutes. You can watch full movies using services like Netflix, hulu, HBO, torrent etc.
How long is The Invention of Lying?The Invention of Lying has a total playtime of 100 minutes.


text:
RIHANNA EX'S QUICK CHECKOUT
Amber Sutherland
Social Links for Amber Sutherland
If Rihanna and Chris Brown made sweet music together at a Midtown hotel, it was just a few notes.
Brown, under court order to avoid his ex-gal pal, checked out less than two days after both singers ended up in separate rooms of the Trump International Hotel & Tower on Columbus Circle. He split because of the paparazzi stalking the building, a source told The Post.
Rihanna's rep confirmed the pretty songstress and Brown were at the same hotel, but insisted they never saw each other.
"It was just a coincidence. She has stayed there before," said publicist Amanda Silverman, adding that her client had no worries about Brown being in the same hotel.
Brown, 20, pleaded guilty to beating Rihanna, 21, in February, and will be sentenced on Aug. 5 in Los Angeles. A judge ordered Brown to stay 50 yards away from his ex.
No witnesses have come forward to say the former lovers were together over the weekend.
Read Next PALIN STEPS DOWN
30-year-old NJ official shot and killed outside her home: reports


Looking for ideal Backhoe Loader Accessories Manufacturer & supplier ? We have a wide selection at great prices to help you get creative. All the Backhoe Loader Description are quality guaranteed. We are China Origin Factory of Backhoe Loader Hs Code. If you have any question, please feel free to contact us.


text:
South Park Slot
If you're one of those people who has been living under a rock for the past two decades, then allow us to explain all about South Park. It's an American adult animated sitcom, which is created by Trey Parker and Matt Stone for the Comedy Central television network. The show centres around four boys, those being Stan Marsh, Kyle Broflovski, Eric Cartman and Kenny McCormick. They frequently end up being involved in many disastrous adventures around the town of South Park, Colorado. Due to its use of crude language and dark, surreal humour, the show is intended only for viewing by mature audiences. It was first broadcast on television in August of 1997 to rave reviews, and to this day it still remains as one of Comedy Central's highest rated shows. Because of its huge success, it has spread across to many forms of media, including video slots like this one created by NetEnt. The game itself is full of humour and good-natured fun, transporting you to the South Park town to go on an adventure of your own with the show's characters. So join us as we look through what makes this product so good.
Top 10 NetEnt Casinos
#1 View Casino
Safety & Reliability:
Bonuses & Gamification
Game Choice:
100% Up to €300*
100 Free Spins*
120 Wager-Free Spins*
30 Wager-Free Spins*
50 Free Spins*
100 Free Spins on Starburst*
#10 View Casino
100% up to €50
100% Up to €50*
100%, up to €100
100% Up to $/€ 333*
Wager-Free Bet*
50 Spins + 20 Coins*
100%, up to €100*
4,200 extra spins + 11 wager-free welcome spins
Bonuses & Rewards:
200% Bonus, up to €50
#1 Fun Casino
100% up to £100 Visit Casino
#2 Prospect Hall
100% Up to €300* 100 Free Spins* Visit Casino
#3 Kerching!
100% Up to €500* 150 Visit Casino
#4 Volt
120 Wager-Free Spins* Visit Casino
#5 Just Casino
100% up to €200* Visit Casino
#6 Voodoo Dreams
100% up to €100 200 Free Spins Visit Casino
#7 Casumo
Bonus up to €300* 30 Wager-Free Spins* Visit Casino
#8 Vegas Hero
100% up to €200* 50 Free Spins* Visit Casino
#9 Pots Of Luck
100% up to €100* 100 Free Spins on Starburst* Visit Casino
#10 Cashmio
100% up to €50 100 Free Spins Visit Casino
#11 Casino Heroes
100% Up to €50* Visit Casino
#12 Dunder
#13 Genesis Casino
100%, up to €100 300 Free Spins Visit Casino
#14 GoWild Casino
100% Up to $/€ 333* Visit Casino
#15 Highroller
Wager-Free Bet* 50 Spins + 20 Coins* Visit Casino
#16 Leo Vegas
- - Visit Casino
#17 Mr Green
100%, up to €100* 200 Free Spins* Visit Casino
#18 Spinit Casino
100% up to €1000 200 Free Spins Visit Casino
#19 Videoslots
100% up to €200 4,200 extra spins + 11 wager-free welcome spins Visit Casino
#20 Trada
200% Bonus, up to €50 Visit Casino
NetEnt Stalker Online:
Casino of the Year
Read Casino Review
Up to €300 + 30 Wager-Free Spins*
For all new players at Casumo
Arcane Reel Chaos...
Reely Good Reels!
You'll find that there isn't anything specifically different about the general layout of this game when compared to other video slots. So, you'll get the standard five reel and three row interface to play on. On the reels, you'll find the various different symbols, which start with the often seen A, J, K and Q icons. These are joined by the four boys from the show, each decked out in their primary outfits. So, there's Stan with his blue and red bobble hat, Kyle with his green ushanka hat, Kenny zipped up as usual in his orange coat so that only his eyes are visible, and Cartman in his trademark blue hat and red coat. Other characters from the show also make appearances in the game's special features, which we'll go through a little later on.
As far as the remainder of the interface goes, players will be able to place wagers on a total of 25 different pay lines. These cannot be customised in any way, so you'll always be betting on this amount. However, you do have the chance to set your own wager amount, which starts by adjusting the bet level. This offers up a range of between one and 10. Meanwhile, on the other side of the screen, you have the option of altering the coin value, and this provides you with a choice of between €0.01 and €1 per line. Therefore, altogether, you're able to place a maximum overall bet of €250 per spin, which is a total that can instantly be reached with the 'Max Bet' button.
More NetEnt Slots
Arcane Reel Cha...
Scudamore'...
Mercy of the Go...
Golden Grimoire...
Strolling Staxx...
Turn Your Fortu...
Trada Casinp &#...
Fire Siege Fort...
A Multitude of Sweet Specials!
There's a nice choice of specialities included in the game, which starts with the added wild icon. These can appear on any of the reels in the base game, as well as in the Kyle Bonus Spins extra. As a wild, this icon will substitute for any other symbol on the reels, except for the bonus icons, and they'll only substitute for the highest possible winning combination on a bet line. However, this icon is just the start of the special features of this game.
There are four different bonus games, and these are each activated by two regular bonus symbols appearing anywhere on reels three and four only, simultaneously to one character bonus symbols appearing on reel five. The bonus round which is activated is dependant on which character bonus icon is in view. These are broken down as follows:
Kyle Bonus Spins. This provides you with 10 freespins of the reels, and when the Ike Wild symbol shows up on the fifth reel, Ike lands randomly on one of the tiles below the reels to activate on of the following features: Multipliers between times two and times 10, a coin win between 50 and 500, or +3 additional freespins.
Kenny Bonus Game. Here, you'll need to guide Kenny through the three different types of zones, those being the win, multiplier and danger zone. The first contains only coin wins, the second contains varied multipliers, and the third provides a single trap, which causes an accident, as well as coin wins.
Cartman Bonus Game. This provides you with four randomly generated outcomes – coin win, double up, reset, or warning/game over. You simply need to click on the various yellow bushes to reveal the prizes.
Stan Bonus Spins. At the start of this round, a sticky wild appears in the centre of reel three and remains there for two spins. They can then appear anywhere on the reels, and will stand in for other icons to form a win. This round continues as long as there is at least one sticky wild present on the reels.
It still doesn't end yet, as there are three mini-features as well in the 'Terrance and Phillip' round, who randomly place three wilds anywhere on the middle three reels, the 'Mr Hankey' feature, who activates between three and five wild icons, and the 'Cartman' mini feature, which sees a block of 3×3 wilds appear on the reels.
There are few games as cram packed with features as this one is, and we love it for all of them and more!
South Park Slot South Park Slot 0 0


Where's this one meant to be?
Manchester, heading south from the city centre.
It's also partially in existence. Sort of.
Well, it's all a little bit confusing, so you'll have to bear with me.
Currently, the Princess Parkway is the section of A5103 immediately to the north of M56 junction 3, the main access to Manchester from the south. Despite the fact that colloquially the rest of A5103 is known as "The Parkway", it's actually Princess Road.
Maybe surprisingly, the Princess Parkway has a long history - going back to the late 1920s.
What's that got to do with a motorway then?
Just bear with me on this, OK?
At that time, Princess Road stopped dead at Barlow Moor Road (A5145). South of there, the now-Manchester suburb of Wythenshawe was founded as a planned community, one of the "garden estates" of the time. Princess Parkway was planned to be a gateway to that community, a wide parkland-setting access road and not a through route. It met Princess Road end on, and ran to Altrincham Road (A560) and was opened in February 1932.
Its status as a pleasant access was under threat pretty much from the beginning. In 1936, tentative plans were published by Cheshire County Council and Manchester City Council to extend the Parkway, both northwards to the then-city boundary, and south towards Knutsford. These plans were firmed up somewhat by their inclusion in the 1945 City of Manchester Plan, which, as you can imagine, pleased the residents of Wythenshawe no end.
The 1962 SELNEC Highways Plan went further.
The Princess Parkway was to be widened to become a motorway, and not only that, would be extended far to the north and south.
The section to the south of the Parkway became known, frighteningly enough, as the "Princess Parkway Extension", and met the North Cheshire Motorway near Bowdon. This whole section is now open as the M56, and included the Manchester Airport Spur - part of the original southern section of the Manchester Outer Ring Road. This section opened in 1972.
Princess Parkway itself was widened and improved to motorway standards in 1974. Indeed, for the uninformed, it looks pretty much like the M56 immediately to the south. There's a hard shoulder, and either three or four lanes in each direction.
Yeah, it is. I reckon that most people don't even notice they've left the motorway proper.
Anyway, shall we talk a little bit about the bit north of there?
The rest of A5103 Princess Road north of M60 is an everyday dual carriageway, with pedestrian crossings, traffic light junctions, houses and shops alongside. However, take a closer look, and there's one or two slightly odd things about it.
Well, let's take the houses and shops first. Along most of its length, Princess Road only has shops and houses down the eastern side of the road. Pretty much all the way along the western side north of A5145 Barlow Moor Road the development is set back quite some way. There are playing fields, and large flat grassed areas, with only post-1990 temporary "tin shed" buildings, a few houses just to the north of the A6010 Wilbraham Road junction and one pub left.
Even the old Hulme Crescents were set back a long way from the road, in a manner reminiscent of Fort Ardwick along the A57 to the east of the city - and for the same reason too. Whilst the A57 Hyde Road has plenty of land around it for the M67 Manchester - Sheffield Motorway, Princess Road, more subtly, has the land reserved for the Princess Parkway Motorway.
Then as we get further north, we meet the Greenheyes Lane junction. It's absolutely massive, over an enormous area - and Greenheyes Lane is a really quite wide dual carriageway at this point too, before turning to rubbish either side. All of which, especially given that Greenheyes Lane just isn't an important road - heck, it's not even a classified road, is all rather odd.
It turns out that Greenheyes Lane is exactly on the line of the never-built Manchester and Salford Inner Ring Road, and the junction there is a temporary affair waiting for the two motorways to cross at a roundabout junction that will, of course, never arrive.
North of there, it's even more obvious that something's going on. There's a large gap between the two carriageways that narrows pretty much right in the middle of the section between Greenheyes Lane and the A57(M) Mancunian Way - exactly the layout as if two sliproads were to come off the junctions at either end, and meet the mainline of the motorway somewhere in the middle. There's also these two awfully convenient roads to either side, that would have served local traffic without it having to join the motorway proper. Rather irritatingly, neither of them is now in use as intended - the one on the western side has been converted to a cyclepath, whilst the one on the eastern side is now access to a Land Rover dealership, as well as a cyclepath. It's is alleged that this section opened with motorway-style "NO" signs, listing the restrictions in effect on the road.
So where on earth would the motorway have ended?
At yet another unbuilt road - the City Centre Road. The end of the Princess Parkway Motorway would have been at a large roundabout roughly where the Whitworth Street/Albion Street junction is today.
Yes, it is rather, but that's not the end of the story?
Well, the motorway makes it into the 1971 SELNEC Transportation Study, where there's a small twist or two added in.
There appears to be two slightly conflicting versions of the motorway in the plan. They both follow the same route, and have the same junction layouts, but there's one thing that's a little different: what happens in the centre of the motorway.
In both plans, the central section is two lanes wide, and removed from the rest of the motorway. Heading northwards, it could only be accessed from the point where the present M60 junction sliproads leave Princess Parkway, and from that point until the Inner Ring Road, you're stuck on it. This would have formed a section which, in theory at least, should move more freely than the main motorway for people travelling between the central area and Cheshire.
In the first plan, this section would have operated on a tidal flow basis: closed for most of the day, but open for two extra lanes heading into the city during the morning rush hour, and two extra lanes heading out of the city during the evening peak.


text:
Robert Dietz (* 11. November 1949 in Straubing) ist ein ehemaliger deutscher Eistänzer.

Er wurde 1977 mit seiner Partnerin Gabriele Schäfer in Garmisch-Partenkirchen deutscher Meister im Eistanz. 1976 startete das Paar bei den Weltmeisterschaften und belegte den 19. Platz. Dies blieb ihr einziger Start bei Europa- und Weltmeisterschaften.

Dietz studierte Chemie an der TU in München. Heute ist er verheiratet, hat 2 Kinder und lebt in Weinheim an der Bergstraße.

Erfolge/Ergebnisse

 J = Junioren

Deutscher Meister (Eiskunstlauf)
Eiskunstläufer (Deutschland)
Deutscher
Geboren 1949
Mann


In Australia they would not say, "April showers brings May's flowers." We are currently in Spring. Yes, our seasons are exactly opposite of America. It really is hard to wrap my mind around, October isn't a time for boots, sweaters, pumpkin, and blankets. November isn't for warm blankets, fall colors, and running in long sleeves. December isn't a time where you secretly hope you have a white Christmas. Here December is a time for "July" heat. November is a time for flowers to bloom, and October is a time for spring.
All the time, I catch myself looking on Facebook, Instagram, or other blogs thinking, "oh, that is cute. I should get that since winter is coming up." HA! No, winter is in June here. I also catch myself when people say something is in December, I automatically think, "Oh! that is a long way from now. It is still summer."
So, while I am still trying to wrap my mind around seasons are opposite throughout the year, and the fact that Queensland has two seasons, comfortable and hot. I have decided to just enjoy flowers and nature.
I am trying to make myself stop and take a picture or just stop and soak in natural beauty around me, when I find myself getting hot, or getting confused with the seasons. We are so blessed to live in such a beautiful country.
These are some of the pictures I have taken. I love to add words to them later. I love nature, all the details that are paid attention to in nature are amazing. All I can think about is, "Isn't God creative?" Can you imagine creating everything? I think it would have been so fun to be a fly on the wall when God was trying to pick all the colors and designs for the world.
What is one of your favorite sayings? You never know, it might end up on a picture. So for now, I am really enjoying taking pictures of nature, making the most out of my time here, and learning all about a climate with only two seasons.


1818, from Latin efflorescentem (nominative efflorescens), present participle of efflorescere (see effloresce).
In nothing is it akin to Isabella's efflorescent Plateresque-Gothic.
By careful evaporation, efflorescent prismatic crystals may be obtained, soluble in 41⁄2 parts of water.
And then the long hotel piazza came in view, efflorescent with the full-toiletted fair.
Their ordinary speech was ornate and efflorescent, throwing itself out in simile and hyperbole.
To be so near the reality, the literal flesh and blood of what had been a long series of efflorescent dreams, quite stirred him.
In April the mating season would be over and the birds silent, a brooding stillness possess an efflorescent Eden.
Their edges should be smeared with candle-grease, to prevent the salt creeping over them by efflorescent vegetation.
I hope these efflorescent days (if you have them) don't turn your stomach too much against the thick taste of the Julian broth.
Gilfoyle's forgotten affections came back to life, expanding and efflorescent.
This salt, in its efflorescent state, exists extensively in the limestone caves of Missouri and Arkansas.


text:
Rosenberg's Department Store is located at Fourth and D Streets in downtown Santa Rosa, California. The structure is the most significant example of the Streamline Moderne style in Santa Rosa, and was the tallest building in the city for many years.

History
The store was planned to replace a 1907 store owned by Max and Fred Rosenberg that burned in 1936. The design for the new store was carried out by Hertzka and Knowles of San Francisco in 1936, and construction by contractors Moore and Roberts started on January 19, 1937.  The store opened on October 27, 1937, along with the Purity grocery store in a one-story section.

A model of the building was shown as "an exemplar of future architectural technology" at the 1939 San Francisco World's Fair.

In 1951 Joseph Edward McNeany purchased Rosenberg's for $1.5 million. The store was substantially renovated and expanded in 1964. After modernizing the three-story store it was merged in 1966 with Aldens Inc., a Chicago-based mail order and retail sales subsidiary of Gambel-Skogmo. Under terms of the agreement, McNeany stayed on as a consultant and his son, William, became vice president and general manager of Rosenberg's.   It closed in 1988 and was vacant until 1994. That year, the Art Deco Society of California recognized the structure with its Preservation Award in 1988 to encourage the building's owners to save the structure.

The city government approved demolition of the store in 1994, but it was subsequently saved when bookstore chain Barnes & Noble leased the space. The building was placed on the National Register of Historic Places on December 29, 1994.

Description
Rosenberg's is a two-story structure measuring about  by , with an attached  by  one-story section. The front is dominated by an Art Moderne style marquee and sign that extends beyond the roof, with the main entrance under the marquee. The steel-framed structure is clad with stucco-covered cast in place concrete. The lower level features continuous plate glass display windows, with a curved corner above set apart by string courses or "speed lines", inset with glass block clerestory windows. Large punched openings with keystone-like vertical stripes define the second floor bays. The marquee section is defined by flanking pylons embracing a tall, glass block window whose surface undulates. A fin or "blade sign"  rises from the top of the window to about  above the roof, where it originally carried neon lettering advertising the store. A taller fin is set back and rises much higher, to  above the roof. It is translucent, and was internally lighted with green neon. The one-story section is much plainer, with a continuous canopy across the front. The entrance to this section is marked by two arches in the canopy.

The interior has a high-ceilinged section overlooked by a mezzanine. Interior columns have capitals resembling Egyptian prototypes. The mezzanine and stair railings are slender horizontal bars with birch handrails.

References

National Register of Historic Places in Sonoma County, California
Streamline Moderne architecture in California
Commercial buildings completed in 1937
Buildings and structures in Santa Rosa, California
Commercial buildings on the National Register of Historic Places in California
Department stores on the National Register of Historic Places
Economy of Santa Rosa, California


'The Perfect Mother' by Aimee Molloy is a psychological thriller about a group of new moms in one community who call themselves the 'May Mothers' - the mommy group whose sons were all born in the same month. While on a planned night out, one of their newborns is abducted. What follows is a heart-pounding race to find Midas, during which secrets are exposed, marriages are tested, and friendships are destroyed. Need more convincing? Read on for five more reasons you'll want to read this thriller now!


Sailors across the country are preparing for the 2017 Canada Summer Games, kicking off July 28th in Gimli, MB. Gimli Yacht Club will play host to athletes from ten provinces, competing in the Laser Male, Radial Female, 29er Male, 29er Female and 2.4M classes.
Over the last number of weeks and months, sailors have gone through the qualification process to be named to their provincial teams.
Sail Nova Scotia will be sending a full team, with sailors representing their province in each class.
For 2.4M sailor Siobhan MacDonald, this will be her second time competing in the Canada Games. MacDonald competed in the 2013 Canada Summer Games in Sherbrooke, QC, and finishing 4th. In addition, MacDonald has been selected as the flag bearer for Team Nova Scotia in the opening ceremonies on July 28th.
On the other side of the country, Team BC will also have a full contingent of sailors. Including another experienced 2.4M sailor in Delani Hulme Lawrence, who competed in the 2013 Canada Summer Games representing Alberta. Hulme Lawrence finished 5th in 2013.
While BC sailor Henrik Moberg Parker will be competing in his first Canada Games in Gimli, he has was in attendance at the 2001 games in London, ON. Moberg Parker was 6 weeks old at the time, when his mother and BC Sailing Executive Director, Tine Moberg Parker was the sailing Team Manager.
Teams will start to arrive in Gimli on July 27th and focus on boat set-up, training and getting to know the venue before the official practice race on July 29th. The competition officially gets underway on July 30th. Stay tuned to Sail Canada and 2017 Canada Games platforms for updates and news throughout the games!


Free Syllable Lotto Game Board for Preschool and Kindergarten via www.pre-kpages.
Love this big collection of rhyming games and free rhyming activities!
Click on the cover image to download the Phonological Awareness Intervention ebook.
Add a 3rd letter for the child to decode such as mat, sat, pat in the at example or in the sa example sat, sad, sag.
The love of reading starts at home! Here are 10 ways that families can improve their child's reading skills, with or without a hearing loss!
Why is Phonological Awareness So Important?
A phonological awareness game that can be played five different ways to build phonemic awareness.


A US native newspaper has received a Pulitzer Prize for protection of a mass taking pictures in its personal newsroom.
However there used to be no party because the Capital Gazette in Maryland discovered on Monday it had received probably the most prestigious prize in American journalism.
The Capital Gazette in Annapolis received a different Pulitzer Prize quotation for its protection and braveness within the face of one of the crucial deadliest assaults on newshounds in American historical past.
Staff John McNamara, Wendi Winters, Rebecca Smith, Gerald Fischman and Rob Hiaasen died in closing summer time's assault.
However the group of workers nonetheless controlled to submit a newspaper on time table the following day.
A person with a longstanding grudge towards the Capital Gazette is charged with the assault. He pleaded no longer in charge closing 12 months.
The Pittsburgh Publish-Gazette won a breaking information award for its "immersive, compassionate" reporting of closing October's assault at a Pennsylvania synagogue that left 11 other people lifeless.
And the South Florida Solar Sentinel received a Pulitzer for its reporting at the February 2018 mass taking pictures at Marjory Stoneman Douglas Prime College that left 17 lifeless.
It won the general public carrier award for "exposing failings through faculty and cops sooner than and after the fatal taking pictures rampage".
The New York Instances received a prize for explanatory reporting of Mr Trump's price range and tax avoidance and any other for editorial writing.
The Wall Boulevard Magazine received the nationwide reporting prize for uncovering the president's secret payoffs to 2 alleged former mistresses all the way through his marketing campaign.
The Washington Publish additionally received two Pulitzers for photojournalism in Yemen and for grievance.


Rachel Bownik is a writer and filmmaker, currently studying screenwriting and cramming for finals. When she's not taking pictures of bugs and flowers she is making short films about artists, relationships, and ghosts. Many of these videos have had screenings in film festivals. She resides in Minnesota, writing and reading.


If you are in LA, you must visit Universal Studios! Do not forget to buy fast passes or you'll be waiting for hours in lines, so it is really worth it!
That day was by far my best day on the West Coast and I loved every second of it!


text:
About Alexion
Our Ethical Standards
Patient Focus
Soliris®
PNH
aHUS
Strensiq®
Kanuma®
Investigator-Sponsored Research
Discovery Partnerships
Global Access to Medicines Policy
Why Choose Alexion
Recognition & Rewards
Personal Growth & Development
Europe, the Middle East & Africa
Alexion Europe
Alexion Reports Second Quarter 2019 Results
MediaInquiries MediaMaterials EmailAlerts
2Q19 total revenues of $1,203.3 million, a 15 percent increase over 2Q18 and a 23 percent volume increase
2Q19 GAAP diluted EPS of $2.04; non-GAAP diluted EPS of $2.64
Received 3 regulatory approvals - SOLIRIS® (eculizumab) for adults with neuromyelitis optica spectrum disorder (NMOSD) in the U.S., and ULTOMIRIS® (ravulizumab-cwvz) for adults with paroxysmal nocturnal hemoglobinuria (PNH) in Japan and the EU
ULTOMIRIS for atypical hemolytic uremic syndrome (aHUS) under priority review with U.S. FDA
Total revenues and EPS guidance increased to reflect strength of the business and continued growth
Company News, Financial News
Wednesday, July 24, 2019 6:30 am EDT
NASDAQ:
ALXN
BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the second quarter of 2019. Total revenues in the second quarter were $1,203.3 million, a 15 percent increase compared to the same period in 2018. The negative impact of foreign currency on total revenues year-over-year was 1 percent, or $15.1 million, inclusive of hedging activities. On a GAAP basis, diluted EPS in the quarter was $2.04, a 200 percent increase versus the prior year. The second quarter of 2018 included $803.7 million of expense related to the value of the in-process research and development asset acquired in connection with our acquisition of Wilson Therapeutics AB. Non-GAAP diluted EPS for the second quarter of 2019 was $2.64, a 28 percent increase versus the second quarter of 2018.
"We delivered another strong quarter, with continued growth driven by the successful U.S. launches of ULTOMIRIS in PNH and SOLIRIS in gMG. We received three regulatory approvals over the last month, including SOLIRIS for NMOSD in the U.S., and ULTOMIRIS for PNH in Japan and the EU. In addition, the FDA granted priority review for ULTOMIRIS in atypical HUS," said Ludwig Hantson, Ph.D., Chief Executive Officer of Alexion. "We are well positioned to continue our momentum in the second half of 2019, strengthening our four durable franchises in hematology and nephrology, neurology, metabolics and FcRn, advancing and expanding our pipeline, and serving more people living with rare diseases than ever before."
Second Quarter 2019 Financial Highlights
Total net product sales were $1,202.5 million in the second quarter of 2019, compared to $1,044.7 million in the second quarter of 2018.
SOLIRIS® (eculizumab) net product sales were $980.8 million, compared to $898.2 million in the second quarter of 2018, representing a 9 percent increase. SOLIRIS volume increased 17 percent year-over-year. SOLIRIS net product sales for the second quarter 2019 included a $31.6 million reduction to revenue related to a recent judicial order on SOLIRIS pricing in Canada. The reduction in revenue includes the impact for the period from September 2017 to June 2019.
ULTOMIRIS® (ravulizumab-cwvz) net product sales were $54.2 million in the second quarter of 2019.
STRENSIQ® (asfotase alfa) net product sales were $141.3 million, compared to $125.1 million in the second quarter of 2018, representing a 13 percent increase. STRENSIQ volume increased 21 percent year-over-year.
KANUMA® (sebelipase alfa) net product sales were $26.2 million, compared to $21.4 million in the second quarter of 2018, representing a 22 percent increase. KANUMA volume increased 33 percent year-over-year.
GAAP cost of sales was $99.2 million, compared to $95.3 million in the second quarter of 2018. Non-GAAP cost of sales was $95.7 million, compared to $89.3 million in the second quarter of 2018.
GAAP R&D expense was $187.6 million, compared to $173.4 million in the second quarter of 2018. Non-GAAP R&D expense was $148.7 million, compared to $158.3 million in the second quarter of 2018.
GAAP SG&A expense was $299.3 million, compared to $277.3 million in the second quarter of 2018. Non-GAAP SG&A expense was $255.8 million, compared to $230.4 million in the second quarter of 2018.
GAAP acquired in-process research and development expense (benefit) was $(4.1) million related to the agreement of the final working capital adjustment for the Syntimmune, Inc. acquisition, compared to $803.7 million in the second quarter of 2018, related to the in-process research and development asset acquired in connection with the 2018 acquisition of Wilson Therapeutics AB.
GAAP income tax expense was $39.7 million, compared to income tax expense of $38.8 million in the second quarter of 2018. Non-GAAP income tax expense was $90.2 million, compared to $77.1 million in the second quarter of 2018.
GAAP diluted EPS was $2.04, compared to $(2.05) in the second quarter of 2018. The second quarter of 2018 included $803.7 million of expense related to the value of the in-process research and development asset acquired in connection with the Wilson Therapeutics AB acquisition. Non-GAAP diluted EPS was $2.64, compared to $2.07 in the second quarter of 2018.
SOLIRIS - Neuromyelitis Optica Spectrum Disorder (NMOSD): In June 2019, the U.S. Food and Drug Administration (FDA) approved SOLIRIS for adults with anti-aquaporin-4 (AQP4) auto antibody-positive NMOSD. Applications for approval in the European Union (EU) and Japan are under review. Alexion plans to initiate a Phase 3 study in children and adolescents with NMOSD by the end of 2019.
SOLIRIS - Generalized Myasthenia Gravis (gMG): Dosing is underway in a Phase 3 study of SOLIRIS in children and adolescents with gMG.
ULTOMIRIS - Paroxysmal Nocturnal Hemoglobinuria (PNH): ULTOMIRIS was approved for adults with PNH in Japan in June 2019 and in the EU in July 2019. A Phase 3 study of ULTOMIRIS in children and adolescents with PNH is underway.
ULTOMIRIS - Atypical Hemolytic Uremic Syndrome (aHUS): In June 2019, Alexion announced that the FDA granted priority review for ULTOMIRIS in aHUS and set a Prescription Drug User Fee Act (PDUFA) target action date of October 19, 2019. The filing was based on previously announced positive topline results from a Phase 3 study of ULTOMIRIS in complement inhibitor-naïve patients with aHUS. Alexion plans to file for regulatory approvals in the EU and Japan in the second half of 2019. In addition, a Phase 3 study of ULTOMIRIS in children and adolescents with aHUS is underway.
ULTOMIRIS - Subcutaneous: Dosing is underway in a single, PK-based Phase 3 study of ULTOMIRIS delivered subcutaneously once per week to support registration in PNH and aHUS. Data are expected in early 2020.
ULTOMIRIS - gMG: Dosing is underway in a Phase 3 study of ULTOMIRIS in gMG.
ULTOMIRIS - NMOSD: Alexion plans to initiate a Phase 3 study of ULTOMIRIS in NMOSD by the end of 2019, pending regulatory feedback.
ULTOMIRIS - Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA): Alexion plans to initiate a Phase 3 study of ULTOMIRIS in HSCT-TMA in the first half of 2020, pending regulatory feedback.
ALXN1840 (WTX101) - Wilson Disease: Dosing is underway in a Phase 3 study of ALXN1840 (WTX101) in Wilson disease, a rare genetic disorder with devastating hepatic and neurological consequences. ALXN1840 is a first-in-class oral copper-binding agent with a unique mechanism of action to bind serum copper and promote its removal from the liver. Enrollment is expected to complete in early 2020.
PHASE 1/2
ALXN1830 (SYNT001): Alexion plans to initiate a Phase 2/3 study of ALXN1830 (SYNT001) in warm autoimmune hemolytic anemia (WAIHA) in early 2020. In addition, Alexion plans to initiate a Phase 1 study of a subcutaneous formulation of ALXN1830 in healthy volunteers in early 2020. Pending results from the Phase 1 study, Alexion plans to initiate a Phase 2/3 study of subcutaneous ALXN1830 in gMG in 2020.
ALXN1810 - Subcutaneous: Alexion has completed a Phase 1 study of subcutaneous ALXN1210 co-administered with Halozyme's ENHANZE® drug-delivery technology, recombinant human hyaluronidase enzyme (rHuPH20), a next-generation subcutaneous formulation called ALXN1810. Strategic planning for the best development path for ALXN1810 is ongoing.
ULTOMIRIS - Amyotrophic Lateral Sclerosis (ALS): Alexion plans to initiate a proof-of-concept study for ULTOMIRIS in ALS in early 2020, pending regulatory feedback.
ULTOMIRIS - Primary Progressive Multiple Sclerosis (PPMS): Alexion plans to initiate an exploratory clinical study of ULTOMIRIS in PPMS.
Caelum Biosciences - CAEL-101 - Light Chain (AL) Amyloidosis: Alexion is collaborating with Caelum Biosciences to develop CAEL-101 for AL amyloidosis, a rare systemic disorder that causes misfolded immunoglobulin light chain protein to build up in and around tissues, resulting in progressive and widespread organ damage. CAEL-101 is a first-in-class amyloid fibril targeted therapy designed to improve organ function by reducing or eliminating amyloid deposits in patients with AL amyloidosis. In a Phase 1a/1b study, CAEL-101 demonstrated improved organ function, including cardiac and renal function, in patients with relapsed and refractory AL amyloidosis. Pending regulatory feedback, a Phase 2/3 study investigating CAEL-101 as an add-on to current standard-of-care therapy is planned to begin in 2020.
Affibody AB - ABY-039: In April 2019, Alexion entered into a partnership with Affibody AB, following approval from the relevant regulatory authorities, to co-develop ABY-039 for rare Immunoglobulin G (IgG)-mediated autoimmune diseases. Currently in Phase 1 development, ABY-039 is a bivalent antibody-mimetic that targets the neonatal Fc receptor (FcRn). ABY-039 has been specifically designed to combine Affibody's protein therapeutics platform (Affibody® molecules) and AlbumodTM technology to achieve a long half-life, which, along with its small size provides the potential for less frequent, convenient, at-home subcutaneous administration.
ALXN1720: In June 2019, Alexion submitted the initial Clinical Trial Authorization (CTA) application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the initiation of a Phase 1 study of ALXN1720, a novel anti-C5 albumin-binding bi-specific mini-body that binds and prevents activation of human C5. Alexion plans to initiate this first-in-human study in late 2019.
Zealand Pharma A/S: Alexion is collaborating with Zealand Pharma A/S to discover and develop novel peptide therapies for up to four targets in the complement pathway. Peptides offer a number of advantages, including being highly selective and potent, allowing low dosage volumes for ease of administration, and having the potential to treat a broad range of complement-mediated diseases.
Dicerna - GalXCTM: Alexion is collaborating with Dicerna Pharmaceuticals to jointly discover and develop up to four subcutaneously delivered GalXCTM RNA interference (RNAi) candidates, currently in pre-clinical development, for the treatment of complement-mediated diseases.
Complement Pharma - CP010: Alexion is collaborating with Complement Pharma to co-develop CP010, a pre-clinical C6 inhibitor that has the potential to treat multiple neurological disorders.
2019 Financial Guidance
Alexion is increasing total revenues and EPS guidance. Full guidance updates are outlined below.
Previous (as of April 25, 2019)
Updated (as of July 24, 2019)
$4,675 to $4,750 million
SOLIRIS/ULTOMIRIS revenues
Metabolic revenues
$655 to $680 million
R&D (% total revenues)
Non-GAAP
SG&A (% total revenues)
Updated 2019 financial guidance assumes a GAAP effective tax rate of 6 to 7 percent and a non-GAAP effective tax rate of 14 to 15 percent.
Alexion's financial guidance is based on current foreign exchange rates net of hedging activities and does not include the effect of acquisitions, license and collaboration agreements, intangible asset impairments, litigation charges, changes in fair value of contingent consideration or restructuring and related activity outside of the previously announced activities that may occur after the issuance of this press release.
Conference Call/Webcast Information:
Alexion will host a conference call/audio webcast to discuss the second quarter 2019 results today at 8:00 a.m. Eastern Time. To participate in the call, dial 866-762-3111 (USA) or 210-874-7712 (International), conference ID 5564357 shortly before 8:00 a.m. Eastern Time. A replay of the call will be available for a limited period following the call. The audio webcast can be accessed on the Investor page of Alexion's website at: https://ir.alexion.com/.
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies. As the global leader in complement biology and inhibition for more than 20 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), as well as the first and only approved complement inhibitor to treat atypical hemolytic uremic syndrome (aHUS), anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). In addition, the company is developing several mid-to-late-stage therapies, including a second complement inhibitor, a copper-binding agent for Wilson disease and an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases as well as several early-stage therapies, including one for light chain (AL) amyloidosis and a second anti-FcRn therapy. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology and metabolic disorders. Alexion has been named to the Forbes' list of the World's Most Innovative Companies seven years in a row and is headquartered in Boston, Massachusetts' Innovation District. The company also has offices around the globe and serves patients in more than 50 countries. This press release and further information about Alexion can be found at: www.alexion.com.
[ALXN-E]
This press release contains forward-looking statements, including statements related to: guidance regarding anticipated financial results for 2019 (and the assumptions related to such guidance); the strength of our business and continued growth; plans to expand the Company's pipeline; Company's goal of continuing to build on momentum as the year progresses; further future growth in the Company's four durable franchises (hematology/nephrology, metabolics, neurology and FcRn); plans to make future regulatory submissions/filings for approval of certain of our products and product candidates, including SOLIRIS (eculizumab) and ULTOMIRIS (ALXN1210 /ravulizumab-cwvz), and the expected timing related thereto, (as well as the expected timing of the receipt of certain regulatory approvals to market a product); future plans for, and the timing for, the commencement of future clinical trials and the expected timing of the receipt of results of certain clinical trials and studies; potential benefits of current products and products under development and in clinical trials (including further extended dosing intervals); Company's plans to initiate proof-of-concept studies for ULTOMIRIS in ALS and exploratory clinical study for ULTOMIRIS in PPMS; the potential to treat a broad range of complement mediated diseases with the product to be developed with Zealand Pharma A/S; and Alexion's future clinical, regulatory, and commercial plans for ULTOMIRIS and other product candidates. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ materially from those forward-looking statements, including for example: our dependence on sales from our principal product (SOLIRIS); our ability to facilitate the timely conversion of PNH patients (and any future indications) from SOLIRIS to ULTOMIRIS; payer, physician and patient acceptance of ULTOMIRIS as an alternative to SOLIRIS; appropriate pricing for ULTOMIRIS; future competition from biosimilars and novel products; decisions of regulatory authorities regarding the adequacy of our research, marketing approval or material limitations on the marketing of our products; delays or failure of product candidates to obtain regulatory approval; delays or the inability to launch product candidates due to regulatory restrictions, anticipated expense or other matters; interruptions or failures in the manufacture and supply of our products and our product candidates; failure to satisfactorily address matters raised by the FDA and other regulatory agencies; results in early stage clinical trials may not be indicative of full results or results from later stage or larger clinical trials (or broader patient populations) and do not ensure regulatory approval; the possibility that results of clinical trials are not predictive of safety and efficacy and potency of our products (or we fail to adequately operate or manage our clinical trials) which could cause us to halt trials, delay or prevent us from making regulatory approval filings or result in denial of approval of our product candidates; unexpected delays in clinical trials; unexpected concerns that may arise from additional data or analysis obtained during clinical trials; future product improvements may not be realized due to expense or feasibility or other factors; uncertainty of long-term success in developing, licensing or acquiring other product candidates or additional indications for existing products; inability to complete planned acquisitions due to failure of regulatory approval or material changes in target or otherwise; inability to complete acquisitions and investments due to increased competition for technology; the possibility that current rates of adoption of our products are not sustained; the adequacy of our pharmacovigilance and drug safety reporting processes; failure to protect and enforce our data, intellectual property and proprietary rights and the risks and uncertainties relating to intellectual property claims, lawsuits and challenges against us (including intellectual property lawsuits relating to ULTOMIRIS brought by third parties against Alexion and inter partes review petitions submitted by third parties); the risk that third party payors (including governmental agencies) will not reimburse or continue to reimburse for the use of our products at acceptable rates or at all; failure to realize the benefits and potential of investments, collaborations, licenses and acquisitions; the possibility that expected tax benefits will not be realized; assessment of impact of recent accounting pronouncements; potential declines in sovereign credit ratings or sovereign defaults in countries where we sell our products; delay of collection or reduction in reimbursement due to adverse economic conditions or changes in government and private insurer regulations and approaches to reimbursement; uncertainties surrounding legal proceedings, company investigations and government investigations, including investigations of Alexion by the U.S. Securities and Exchange Commission (SEC) and U.S. Department of Justice; the risk that estimates regarding the number of patients with PNH, aHUS, gMG, NMOSD, HPP and LAL-D and other future indications we are pursuing are inaccurate; the risks of changing foreign exchange rates; risks relating to the potential effects of the Company's restructuring; risks related to the acquisition of companies and co-development and collaboration efforts; and a variety of other risks set forth from time to time in Alexion's filings with the SEC, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended March 31, 2019 and in our other filings with the SEC. Alexion disclaims any obligation to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law.
In addition to financial information prepared in accordance with GAAP, this press release also contains non-GAAP financial measures that Alexion believes, when considered together with the GAAP information, provide investors and management with supplemental information relating to performance, trends and prospects that promote a more complete understanding of our operating results and financial position during different periods. The non-GAAP results exclude the impact of the following GAAP items (see reconciliation tables below for additional information): share-based compensation expense, fair value adjustment of inventory acquired, amortization of purchased intangible assets, changes in fair value of contingent consideration, restructuring and related expenses, upfront payments related to licenses and collaborations, acquired in-process research and development assets, impairment of intangible assets, change in value of strategic equity investments, litigation charges, gain or loss on sale of a business or asset and certain adjustments to income tax expense. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for, or superior to, the financial measures prepared and presented in accordance with GAAP, and should be reviewed in conjunction with the relevant GAAP financial measures. Please refer to the attached Reconciliations of GAAP to non-GAAP Financial Results and GAAP to non-GAAP 2019 Financial Guidance for explanations of the amounts adjusted to arrive at non-GAAP net income and non-GAAP earnings per share amounts for the three and six month periods ended June 30, 2019 and 2018 and projected twelve months ending December 31, 2019.
(Tables Follow)
ALEXION PHARMACEUTICALS, INC.
TABLE 1: CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Six months ended
Net product sales
Selling, general and administrative
Acquired in-process research and development
Amortization of purchased intangible assets
Change in fair value of contingent consideration
(22.6
Restructuring expenses
Total operating expenses
(400.1
Other income and expense:
Investment (expense) income
Other income and (expense)
Income tax (benefit) expense
Net income (loss)
Earnings (loss) per common share
Diluted
Shares used in computing earnings (loss) per common share
TABLE 2: RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS
GAAP net income (loss)
Before tax adjustments:
Cost of sales:
Share-based compensation
Restructuring related expenses (1)
Research and development expense:
Upfront payments related to licenses and collaborations (2)
Selling, general and administrative expense:
Litigation charges(3)
Acquired in-process research and development (4)
Change in fair value of contingent consideration (5)
Restructuring expenses (1)
Investment income:
Change in value of strategic equity investments (6)
Other income:
Adjustments to income tax (benefit) expense (7)
Non-GAAP net income
GAAP earnings (loss) per common share - diluted
Non-GAAP earnings per common share - diluted
Shares used in computing diluted earnings (loss) per common
share (GAAP)
Shares used in computing diluted earnings per common share (non-
GAAP)
The following table summarizes the total restructuring and related expenses recorded by type of activity and the classification within the Reconciliation of GAAP to non-GAAP Financial Results:
Three months ended June 30,
Asset-
Selling, general and
Restructuring expense
Other (income) expense
Six months ended June 30,
During the three months ended June 30, 2019, we recorded an upfront license payment of $25.0 million in connection with an agreement that we entered into with Affibody AB (Affibody). During the six months ended June 30, 2019, we recorded upfront license payments of $25.0 million and $21.2 million in connection with agreements that we entered into with Affibody and Zealand Pharma A/S, respectively.
During the second quarter of 2018, we recorded $7.1 million in litigation charges in connection with ongoing investigations.
In connection with the agreement of the final working capital adjustment for the Syntimmune acquisition, we recognized a benefit of $4.1 million associated with previously acquired in-process research and development in the second quarter of 2019. During the second quarter of 2018, we completed the acquisition of Wilson Therapeutics AB. The acquisition was accounted for as an asset acquisition, as substantially all of the fair value of the gross assets acquired is concentrated in a single asset, WTX101, an early Phase III development asset. The value of the acquired in-process research and development asset related to WTX101 was expensed during the three and six months ended June 30, 2018 due to the stage of development of this asset.
For the three months ended June 30, 2019 and 2018, changes in the fair value of contingent consideration expense reflect the interest component of contingent consideration related to the passage of time. Changes in the fair value of contingent consideration expense for the six months ended June 30, 2019 and 2018 include the impact of changes in the expected timing and probability of achieving contingent milestones, in addition to the interest component related to the passage of time.
During the three and six months ended June 30, 2019, we recognized an unrealized (loss) gain of $(25.2) million and $8.6 million, respectively, in investment income to adjust our strategic equity investments to fair value. The six months ended June 30, 2018 included the recognition of an unrealized gain of $100.8 million on our investment in Moderna Therapeutics, Inc. following the completion of a new round of equity financing in the first quarter 2018.
Alexion's non-GAAP income tax expense for the three and six months ended June 30, 2019 and 2018 excludes the tax effect of pre-tax adjustments to GAAP profit. Non-GAAP income tax expense for the six months ended June 30, 2019 also excludes certain one-time tax benefits of $95.7 million and $30.3 million associated with a tax election made with respect to intellectual property of Wilson Therapeutics AB and a release of an existing valuation allowance, respectively. Non-GAAP income tax expense for the six months ended June 30, 2018 also excludes adjustments to provisional estimates of the impact of Tax Cuts and Jobs Act we recorded in fourth quarter 2017.
TABLE 3: RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL GUIDANCE
(in millions, except per share amounts and percentages)
Twelve months ending
Upfront payments related to licenses and collaborations
Change in value of strategic equity investments
Adjustments to income tax expense
Diluted GAAP earnings per common share
Diluted non-GAAP earnings per common share
Operating expense and margin (% total revenues)
GAAP research and development expense
Non-GAAP research and development expense
GAAP selling, general and administrative expense
Non-GAAP selling, general and administrative expense
GAAP operating margin
Non-GAAP operating margin
Income tax expense (% of income before income taxes)
GAAP income tax expense
Tax effect of pre-tax adjustments to GAAP net income and other one-time items
associated with intellectual property
Non-GAAP income tax expense
Amounts may not foot due to rounding.
TABLE 4: NET PRODUCT SALES BY GEOGRAPHY
Total Soliris
ULTOMIRIS
Total Ultomiris
STRENSIQ
Total Strensiq
KANUMA
Total Kanuma
Total Net Product Sales
TABLE 5: CONDENSED CONSOLIDATED BALANCE SHEETS
Trade accounts receivable, net
Prepaid expenses and other current assets (1)
Property, plant and equipment, net (1)
Intangible assets, net
Right of use operating assets (1)
Revolving credit facility
Current portion of long-term debt
Current portion of contingent consideration
Other current liabilities (1)
Long-term debt, less current portion
Contingent consideration
Facility lease obligations (1)
Deferred tax liabilities
Noncurrent operating lease liabilities (1)
Other liabilities (1)
Total stockholders' equity (1)
Total liabilities and stockholders' equity
In February 2016, the Financial Accounting Standards Board issued a new standard that requires lessees to recognize leases on-balance sheet. We adopted the new standard on January 1, 2019 using the modified retrospective approach. The June 30, 2019 condensed consolidated balance sheet is presented under the new standard, while the December 31, 2018 condensed consolidated balance sheet is not adjusted and continues to be reported under the accounting standards in effect for that period. Upon adoption of the new lease standard, we derecognized $472.8 million of property, plant and equipment and other assets and $372.2 million of facility lease obligations associated with previously existing build-to-suit arrangements which resulted in a decrease of $90.3 million to retained earnings, net of tax. In addition, we capitalized $326.1 million and $255.3 million of right of use assets and lease liabilities, respectively, within our condensed consolidated balance sheet upon adoption.
Download Full Size (75.95 KB)
Alexion:
Megan Goulart, 857-338-8634
Senior Director, Corporate Communications
Susan Altschuller, Ph.D., 857-338-8788
Vice President, Investor Relations
Global Privacy Program
This website is intended only for residents of the United States.
© 2020 Alexion